all stops out

Reading this release again shows me that this is an all stops out meeting.

Russian visitors and all

The Directors of Solagran Limited are pleased to advise the market of a shareholder
information evening to be held at 6.00pm on 3 September at the Parkview Hotel in
Melbourne at which shareholders will be given an update in relation to a number of
important technological and strategic developments within the company.
In addition to presentations from Solagran Executive Directors, the information
evening will include presentations from three visitors from Russia: Mr Alexander
Kurganov, Managing Director of SibEX; Dr Tamara Nikitina, Solagran’s Clinical Trials
Co-ordinator; and Ms Marina Orlova, an award winning documentary producer who
has been working for more than a year on a documentary about Solagran and
Bioeffectives® for Russian television.
The Executive Directors will provide a briefing on both strategy and operations and in
so doing, will demonstrate the commercial significance of having a substantial
investment in the world’s first and only commercial scale plant capable of producing
pharmaceutical grade polyprenols (Bioeffective® R) using patent protected
technology.
The Executive Chairman will provide a briefing on marketing activities in relation to
Ropren® in Russia, and report on the high level of interest in both Ropren® and
Bioeffective® A emerging from his participation in a recent infectious diseases
conference convened by the Pasteur Institute.
Mr Kurganov will provide a detailed presentation in relation to the Tomsk production
facility as well as the company’s plans for the construction of a much larger facility
within the Tomsk special economic zone.
Dr Nikitina has been working with Bioeffectives® since the mid 1970s. She will
provide an overview of Solagran’s ongoing clinical trials program and comment on
the results of some recent trials.
Ms Orlova will speak to shareholders about what she has learned in relation to both
Solagran and its Bioeffectives® research program during an extensive period of preproduction
research, followed by more than 6 months filming in Russia. She and her
film crew are in Australia to conduct interviews and to capture the footage they
require for the Australian component of the documentary. It is also planned that
they travel to Dubai to cover the Equine Gastric Ulcer Syndrome (EGUS) trials being
undertaken in conjunction with Solagran’s strategic partner BioProspect Limited.